| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 4
| Issue : 1 | Page : 7 |
|
|
Efficacy and Safety of Conivaptan versus Tolvaptan in Neurocritically Ill Patients
Keaton S Smetana1, Adam L Wiss2, Casey C May1
1 Department of Pharmacy, The Ohio State University Wexner Medical Center, Ohio, Columbus, United States
2 Department of Pharmacy, Saint Thomas West Hospital, Nashville, Tennessee, United States
Correspondence Address:
Dr. Keaton S Smetana
410 W. 10th Ave, Doan Hall Room 368, Columbus, Ohio 43210
United States
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/JTCCM-D-21-00018
|
|
|
Background: Vasopressin receptor antagonists increase serum sodium through increased aquaresis via inhibition of V2 receptors. The purpose of this study was to compare the efficacy and safety of conivaptan versus tolvaptan for the treatment of hyponatremia. Subject and Methods: This was a retrospective study of patients who received conivaptan or tolvaptan for hyponatremia admitted to the neurocritical care unit. Serum sodium values were collected at baseline and daily up to 4 days after the last dose. The primary efficacy outcome was an increase in serum sodium ≥4 mEq/L in 24 h after the first vaptan dose. The primary safety outcome was overcorrection defined by an increase in serum sodium >12 mEq/L in 24 h. Results: Thirty-four encounters (14 conivaptan and 20 tolvaptan) were included. Baseline serum sodium was similar between groups (conivaptan 126 mEq/L and tolvaptan 125 mEq/L). Each group received a median of one vaptan dose received on days 5 and 7 of hospitalization for conivaptan and tolvaptan, respectively. The primary efficacy outcome was similar between conivaptan (9 of 14, 64.3%) and tolvaptan (14 of 20, 70%) groups, P = 1.0, and the median change in serum sodium 24 h after the first vaptan dose was 5 versus 7 mEq/L (P = 0.377), respectively. The rate of overcorrection was similar between conivaptan and tolvaptan patients (7.1% vs. 15% P = 0.627). Conclusion: In this study, conivaptan compared to tolvaptan for the treatment of hyponatremia in patients admitted with a primary neurological diagnosis appears efficacious and safe. Further studies are warranted given the sample size of this cohort.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
